Cross Broder Alliances in Biopharma Industry - Survey Report on Indian Companies

PRLog (Press Release) – Jan 18, 2008 – The Indian biopharmaceutical industry is moving up across the value chain and establishing itself as a basic research-driven, export-oriented industry, providing wide range of value added quality products and services. The industry is fast emerging as a favored destination for many overseas companies especially in the US and EU. In the last two decades, India has emerged as a preferred destination for quality production of active pharmaceutical ingredient (API) coupled with cost effectiveness. At present, India has the largest number of US FDA approved facilities in the world next only to the US. The industry provides better manufacturing services as it has good infrastructure for producing biotechnology products in line with the global standards. The Indian industry is now looking for overseas collaboration and alliances to leverage these advantages.

To understand the Indian biopharmaceutical industry’s views on cross-border alliances, a web-based survey was conducted to capture information on the companies, their plans for entering new markets and leveraging partnerships and alliances for growth and profitability. The survey questionnaire was completed by respondents from Indian companies, of whom 68% were key decision makers. Survey parameters included the strategies of the companies for market expansion, in short run as well as medium term, plans for outsourcing and the types of business models preferred for alliances. This report is useful for the companies to understand the perspectives of the Indian players so as to enable them to formulate the alliance strategies.





Table of Contents : -

Executive summary

1. Introduction

2. Objectives of the study

3. Scope of the report and key findings
3.1 General information on Indian companies, 3.2 Strategic agreements and alliances, 3.3 Indian Companies as users of overseas services, 3.4 Business expansion plans, 3.5 Financial and investment criteria

4. Approach and methodology

5. Analysis and discussion
5.1 General information, 5.1.1 Type of ownership of the company , 5.1.2 Employee strength, 5.1.3 Management control of the companies, 5.1.4 Strategic business areas fetching more than 25% of companies’ revenues, 5.1.5 Therapeutic areas accruing more than 25% of companies’ revenues, 5.1.6 Therapeutic areas attracting more than 25% of companies’ R&D budget, 5.1.7 Mode of operation (Regional), 5.1.8 Regions contributing more than 25% of firms’ revenues, 5.2 Strategic agreements and Alliances, 5.2.1 Current business cooperation / alliance for overseas markets, 5.2.2 Period of alliance initiation, 5.2.3 Indian companies as providers of overseas services/manufacturing, 5.2.4 Types of agreements used to conduct manufacturing/services businesses abroad, 5.3 Indian companies as users of overseas services, 5.3.1 Regions for import of services/technology by Indian companies, 5.3.2 Deal types for using services/tech overseas, 5.4 Business expansion plans, 5.4.1 Future expansion plans in international markets, 5.4.2 Future entry plans in international markets, 5.4.3 Importance of regions for expansion plans, 5.4.4 Timeframe for expansion in US market, 5.4.5 Areas for expansion in the US, 5.4.6 Plan to achieve the entry/expansion into the US, 5.4.7 Factors important to the firm being able to expand/enter in the U.S. market., 5.5 Financial and investment criteria, 5.5.1 Company's annual revenue for FY 2005, 5.5.2 Period in which received the first investment, 5.5.3 Approximate total investments to date from each region, 5.5.4 Seeking capital directly from the U.S. public capital markets, 5.5.5 Preferred sources to seek funds from the US, 5.5.6 Role of the respondents in decision making process

6. Conclusion

For more information, please visit : http://www.bharatbook.com/detail.asp?id=70585